Henry Schein (HSIC) reported $3.14 billion in revenue for the quarter ended June 2024, representing a yearover-year increase of 1.2%. EPS of $1.23 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -4.33% over the Zacks Consensus Estimate of $3.28 billion. With the consensus EPS estimate being $1.22, the EPS surprise was +0.82%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Henry Schein, Inc. (HSIC) registered adjusted earnings per share (EPS) of $1.23 in the second quarter of 2024, down 6.1% from the year-ago period's adjusted EPS. However, the metric exceeded the Zacks Consensus Estimate by 0.8%. Revenues in Detail Henry Schein reported net sales of $3.14 billion in the second quarter, up 1.2% year over year. The metric lagged the Zacks Consensus Estimate by 4.3%. The year-over-year upside reflects an internal sales decline of 2.4%. On a geographic basis, the company recorde ...

Henry Schein (HSIC) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 0.82%. A quarter ago, it was expected that this health care products maker would post earnings of $0.99 per share when it actually produced earnings of $1.10, delivering a surprise of 11.11%. Over the last four quart ...

PRESS RELEASE FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND UPDATES 2024 FINANCIAL GUIDANCE Highlights: ● Second-quarter 2024 GAAP diluted EPS of $0.80, and non-GAAP diluted EPS of $1.23 ● Operating cash flow of $296 million for the second quarter of 2024, year-to-date operating cash flow of $493 million up $192 million compared with year-to-date 2023 ● 2024 full-year non-GAAP EPS guidance updated to $4.70 to $4.82 ● New restructuring plan targeting $75 million to $100 ...

Henry Schein (HSIC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than exp ...

Hims & Hers Health's earnings are expected to surge 281.8% in 2024 compared with the industry's 15.7% growth. HIMS' earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 131% against the industry's 27.1% decline in the past year. HIMS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Haemonetics, sporting a Zacks Rank #1 at present, has an estimat ...

The last time the market acted like this was the late 90s, when a handful of software and internet names skyrocketed. That event was followed by the painful dot-com bust. History doesn't always repeat, but it often rhymes. It could be a terrible mistake betting too heavily on the Magnificent Seven at this juncture. However, the pandemic finally forced a sizable chunk of fixed income activity away from phones and trading desks and onto MarketAxess' platform. Specifically, MKTX has grown revenues from $511 mi ...

Henry Schein Inc. (HSIC) is well positioned to gain from its extensive global foothold and diverse channel mix. Yet, macroeconomic concerns are adversely impacting the company's operational results. The stock carries a Zacks Rank #3 (Hold) currently. Henry Schein has strategically set up distribution centers worldwide to better serve customers and increase its operating efficiency. Apart from North America, the company has a presence in Australia and New Zealand as well as in emerging nations like China, Br ...

What are the Zacks Style Scores? Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. The Zac ...

Group 1 - Zacks Premium offers various tools for investors to enhance their stock market confidence and investment strategies, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores categorize stocks based on value, growth, and momentum characteristics, providing ratings from A to F to indicate potential performance [2][3] Group 2 - The Value Score identifies attractive stocks using financial ratios like P/E and Price/Sales, appealing to value investors seeking undervalued opportunities [3] - The Growth Score focuses on a company's future prospects by analyzing earnings, sales, and cash flow, targeting growth investors [4] - The Momentum Score helps investors capitalize on price trends by assessing recent price changes and earnings estimate shifts [5] Group 3 - The VGM Score combines all three Style Scores, offering a comprehensive view for investors who utilize multiple investing strategies [6] - The Zacks Rank, based on earnings estimate revisions, has shown strong historical performance, with 1 (Strong Buy) stocks averaging a +25.41% annual return since 1988 [7][8] Group 4 - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, maximizing the probability of success [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure if earnings outlooks are negative [10] Group 5 - Henry Schein Inc. (HSIC) is a leading global distributor of health care products, serving various practitioners and operating in 33 countries [11] - HSIC currently holds a 3 (Hold) Zacks Rank with a VGM Score of A and a Momentum Style Score of B, having seen a 5.3% increase in shares over the past month [11][12] - Analysts have revised HSIC's earnings estimate upwards, with the Zacks Consensus Estimate increasing by $0.02 to $5.08 per share, indicating a solid investment opportunity [12]